
QMS Medical Q2 FY24 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 3
Margin
Category 3
Fundraise
Yes
Order
N/A
Capex
Yes
2 of 4 growth signals are positive.
Full analysisRevenue guidance
Category 3- The company targets a steady revenue growth of around 15-20% annually over the next five years.
- Focus on doubling service business revenue, aiming to cross ₹50 Crores within 2-3 years from the current ₹14-15 Crores.
- Camp business expansion is a key growth driver, with plans to increase daily camps (currently ~75/day), utilizing 65-70% of capacity.
- Growth driven by patient service programs (PSP) and integration with Saarathi post-acquisition, targeting a greater customer base and service expansion.
- Traditional medical device distribution (~₹100 Crores business) expected to grow steadily, providing a stable revenue base.
- Innovation through new product launches, digital marketing (Qdevices with brand ambassador Kapil Dev), and expanding service offerings.
- Consolidation post-acquisition prioritized for the next year before considering further acquisitions or expansions.
See what QMS Medical management said on margin guidance — free account, 30 seconds.
Fundraise plans
Yes- The acquisition funding will be through a combination of internal accruals and bank funding.
- There is a possibility of a capital increase if approved by the board.
- The company has applied with NSE regarding the capital increase.
- If approved, they may explore certain ways and means for the capital increase.
- The primary approach remains internal accrual and bank funding.
- No immediate plans for other acquisitions or fundraising at this moment; focus is on consolidating current acquisition.
See what QMS Medical management said on order book — free account, 30 seconds.
Capex plans
Yes- Current capital expenditures have been made primarily for patient service program equipment, such as diabetic retinopathy machines and BMD machines costing between ₹5-8 lakhs each, with an average equipment worth ₹15-16 lakhs per resource.
- The company expects to recover this capex within a year based on current operations; equipment lifespan is about 6-7 years.
- A recent acquisition of Saarathi Healthcare Services Pvt. Ltd. and Prometheus Healthcare Pvt. Ltd. represents a strategic investment aimed at expanding patient service programs and entering new customer segments.
- The acquisition was funded through a mix of internal accruals and bank funding, with possible capital increase pending board approval.
- No additional acquisitions or major capital investments are planned immediately; focus will be on consolidating current investments and growing the acquired business over the next year.
- The company plans to increase the camp operations capacity by adding 18 more personnel and expanding service offerings post-January after Saarathi integration.
Track QMS Medical — get its next earnings analysis in your feed
How does QMS Medical rank vs peers in Healthcare Equipment & Supplies?
Pro featureHow does QMS Medical rank in Healthcare Equipment & Supplies?
Compare QMS Medical against every Healthcare Equipment & Supplies company (Q2 FY24) on revenue, margins and earnings-call signals.
Continue your research
What QMS Medical's management said in earlier quarters
Others in Healthcare Equipment & Supplies this season
- Fischer Medical (Q2 FY27)
For the quarter ended September 30, 2026, the Standalone revenue from operations was ₹27.62 Lakhs compared to ₹742.69 Lakhs in Q2 FY 2025, showing a…
- Mohini Health (Q2 FY27)
Revenue from operations for the half year ended 30th Sept 2026 is ₹11,043.00 lakhs, compared to ₹7,353.87 lakhs for the half year ended 30th Sept 2025, showing…
- Aprameya Enginee (Q2 FY27)
216.21 lakhs, up 97% year-on-year (YoY). Key results statement takeaways from Aprameya Engineering Ltd's Q2 FY27 results statement — and how it ranks against se
- OSEL Devices (Q2 FY27)
Revenue from operations for H1 FY27: ₹193.6 Cr, up 31.8% YoY from ₹146.9 Cr in H1 FY26 (Page 4, 20). Key investor presentation takeaways from OSEL Devices Ltd's